Cytokinetics (CYTK): EVP Research & Development sold ~$100K
Fady Ibraham Malik, EVP Research & Development at Cytokinetics, sold ~$100K of Cytokinetics shares.
- ~$100K
- Approx. value · 2,000 sh @ $50.14
- 112K
- Holds after · shares reported
- Traded
- Nov 26, 2024
- Filed
- Nov 27, 2024
What stands out in this filing
- The sale was 1.8% of the shares this insider held before it; the filing reports 111,878 shares afterwards.
- 2,000 shares at an average of $50.14 each, as reported on the form.
- Filing box checked: sold under a Rule 10b5-1 plan.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Oct 1, 2024Insider · 1 personInsiders: 2 sales (~$380K)
- Oct 9, 2024InsiderCEO sold ~$278K of CYTK shares in the open market
- Oct 15, 2024Insider · 1 personInsiders: 2 sales (~$396K)
- Oct 28, 2024InsiderDirector sold ~$233K of CYTK shares in the open market
- Oct 30, 2024Insider · 1 personInsiders: 2 sales (~$379K)
- Nov 1, 2024InsiderCEO sold ~$258K of CYTK shares in the open market
- Nov 12, 2024Insider · 1 personInsiders: 2 sales (~$371K)
- Nov 18, 2024InsiderCEO sold ~$253K of CYTK shares in the open market
- Nov 25, 2024InsiderDirector sold ~$37K of CYTK shares in the open market
- Nov 26, 2024 · this disclosureInsiderOfficer sold ~$100K of CYTK shares in the open market
What came next
- Nov 26, 2024InsiderOfficer sold ~$266K of CYTK shares in the open market
- Dec 2, 2024InsiderCEO sold ~$254K of CYTK shares in the open market
- Dec 10, 2024Insider · 1 personInsiders: 2 sales (~$370K)
- Dec 11, 2024InsiderDirector sold ~$90K of CYTK shares in the open market
- Dec 16, 2024InsiderDirector sold ~$36K of CYTK shares in the open market
- Jan 7, 2025InsiderOfficer sold ~$99K of CYTK shares in the open market
- Jan 21, 2025InsiderOfficer sold ~$92K of CYTK shares in the open market
- Feb 4, 2025InsiderOfficer sold ~$96K of CYTK shares in the open market
- Feb 18, 2025InsiderOfficer sold ~$92K of CYTK shares in the open market
- Mar 3, 2025Insider · 3 peopleInsiders: 3 sales (~$528K)
- Mar 4, 2025Insider · 2 peopleInsiders: 2 sales (~$123K)
- Mar 5, 2025InsiderCEO sold ~$1.08M of CYTK shares in the open market
- Mar 6, 2025Insider · 3 peopleInsiders: 3 sales (~$1.2M)
- Mar 13, 2025InsiderOfficer sold ~$1.17M of CYTK shares in the open market
- Mar 14, 2025InsiderOfficer sold ~$4.5K of CYTK shares in the open market
- Mar 17, 2025Insider · 3 peopleInsiders: 5 sales (~$2.9M)
- Mar 18, 2025InsiderOfficer sold ~$87K of CYTK shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Cytokinetics
For Cytokinetics, OQRO holds 26 insider filings (SEC Form 4 or Form 144) and 1 Congress trade report dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CYTK page.
Other recent filings by Fady Ibraham Malik, EVP Research & Development
- SEC Form 4 at Cytokinetics (CYTK)Nov 18, 2026
- SEC Form 4 at Cytokinetics (CYTK)Nov 18, 2026
- SEC Form 4 at Cytokinetics (CYTK)Nov 3, 2026
- SEC Form 4 at Cytokinetics (CYTK)Oct 20, 2026
- SEC Form 4 at Cytokinetics (CYTK)Oct 6, 2026
The full history of Fady Ibraham Malik, EVP Research & Development is on the profile page.
How this filing works
Explore the data
Common questions
Which Cytokinetics (CYTK) insider traded, and how much?
Fady Ibraham Malik, EVP Research & Development at Cytokinetics, sold ~$100K of Cytokinetics shares. 2,000 shares at $50.14.
When did it happen, and when was it made public?
Traded: Nov 26, 2024. Filed: Nov 27, 2024. That is 1 day between the two dates.
What stands out in this filing?
The sale was 1.8% of the shares this insider held before it; the filing reports 111,878 shares afterwards. 2,000 shares at an average of $50.14 each, as reported on the form. Filing box checked: sold under a Rule 10b5-1 plan.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Cytokinetics recently?
For Cytokinetics, OQRO holds 26 insider filings (SEC Form 4 or Form 144) and 1 Congress trade report dated in the last 90 days. They are listed on the CYTK page.
Does this mean CYTK stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Cytokinetics
- SEC Form 4Nov 19, 2026
- SEC Form 4Nov 19, 2026
- SEC Form 4Nov 19, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
Everything OQRO holds on this company is on its CYTK page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
